纤溶酶原激活物抑制剂1型在上皮性卵巢癌中的过表达。

Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.

作者信息

Koensgen D, Mustea A, Denkert C, Sun P M, Lichtenegger W, Sehouli J

机构信息

Department of Gynecology and Obstetrics, University Hospital Charité, Berlin, Germany.

出版信息

Anticancer Res. 2006 Mar-Apr;26(2C):1683-9.

PMID:16617562

Abstract

BACKGROUND

The plasminogen activator-plasmin cascade plays a central role in the progression of solid tumors. The type-1 plasminogen activator inhibitor (PAI-1) is the major physiological regulator of plasminogen activation. PAI-1 is suggested to play a crucial role in tumor cell invasion and metastasis of various solid tumors. The aim of this study was to analyze the clinical and prognostic roles of PAI-1 in epithelial ovarian cancer (OC).

MATERIALS AND METHODS

Expression analysis was conducted by immunohistochemistry and ELISA. Tissue sections of paraffin-embedded tumor specimens and fresh-frozen tumor samples from patients with benign and malignant ovarian tumors (OT), who had undergone surgical intervention in the Department of Gynaecology and Obstetrics, Charité, Germany, from 02/01 to 06/02, were used. Correlation analysis with conventional clinical factors, univariate and multivariate analyses were performed using SPSS (SPSS Inc., V.11.0).

RESULTS

Sixty-five patients (31 primary OC, 20 recurrent OC, 4 low-malignant potential OT, 6 benign OT, 4 normal ovary) were allocated to this trial. The median age was 57 years (range, 34-86) and the median follow-up was 20 months (range, 0-64). The distributions of (FIGO) tumor stage of all primary OC were: I = 16.1%, II = 3.2%, III = 45.2% and IV = 35.5%. PAI-1 was significantly overexpressed in the tumor epithelium of OC in comparison to the ovarian epithelium of benign OT and normal ovary (p < 0.001). The median PAI-1 level was 1.92-fold higher in malignant OT than in benign OT. Statistical analyses showed no significant correlation between the expression of PAI-1 and clinical parameters. The expression of PAI-1 and the PAI-1 level, according to 3 different cut-off values, showed no prognostic impact in univariate analysis. In multivariate analysis, only tumor stage (FIGO) (p = 0.003) and residual tumor (p = 0.009) remained independent prognostic factors for post-operative survival.

CONCLUSION

PAI-1 is significantly overexpressed in OC.

摘要

背景

纤溶酶原激活物 - 纤溶酶级联反应在实体瘤进展中起核心作用。1型纤溶酶原激活物抑制剂（PAI - 1）是纤溶酶原激活的主要生理调节因子。PAI - 1被认为在各种实体瘤的肿瘤细胞侵袭和转移中起关键作用。本研究旨在分析PAI - 1在上皮性卵巢癌（OC）中的临床及预后作用。

材料与方法

通过免疫组织化学和酶联免疫吸附测定进行表达分析。使用了来自德国夏里特妇产科接受手术干预的良性和恶性卵巢肿瘤（OT）患者的石蜡包埋肿瘤标本组织切片和新鲜冷冻肿瘤样本，时间为2001年2月至2002年6月。使用SPSS（SPSS公司，版本11.0）进行与传统临床因素的相关性分析、单因素和多因素分析。

结果

65例患者（31例原发性OC，20例复发性OC，4例低恶性潜能OT，6例良性OT，4例正常卵巢）被纳入该试验。中位年龄为57岁（范围34 - 86岁），中位随访时间为20个月（范围0 - 64个月）。所有原发性OC的（国际妇产科联盟（FIGO））肿瘤分期分布为：I期 = 16.1%，II期 = 3.2%，III期 = 45.2%，IV期 = 35.5%。与良性OT的卵巢上皮和正常卵巢相比，PAI - 1在OC的肿瘤上皮中显著过表达（p < 0.001）。恶性OT中的PAI - 1中位水平比良性OT高1.92倍。统计分析显示PAI - 1的表达与临床参数之间无显著相关性。根据3个不同的临界值，PAI - 1的表达和PAI - 1水平在单因素分析中显示无预后影响。在多因素分析中，只有肿瘤分期（FIGO）（p = 0.003）和残留肿瘤（p = 0.009）仍然是术后生存的独立预后因素。